Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05761743 · ClinicalTrials.gov registry record

Glycemic Control, Type II Diabetes, Parathyroidectomy

A clinical trial of Type 2 Diabetes and Primary Hyperparathyroidism, sponsored by The Cleveland Clinic.

Active
Registry status
80
Enrollment target
1
Study location

NCT05761743: Active study of Type 2 Diabetes and Primary Hyperparathyroidism, sponsored by The Cleveland Clinic.

NCT05761743 is a study of Type 2 Diabetes and Primary Hyperparathyroidism that is active but no longer recruiting, run by The Cleveland Clinic. The registered enrollment target is 80 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05761743, a study of Type 2 Diabetes and Primary Hyperparathyroidism, is active but no longer recruiting, sponsored by The Cleveland Clinic.

ACTIVE NOT RECRUITING
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess glycemic control after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus.

Primary Outcome

Preoperative, operative and postoperative variables will be compared between groups using the unpaired T-test and Chi-squared test for continuous and categorical variables, respectively. Postoperative differences compared to the baseline will be analyzed using a paired T-test.

Interventions

  • DIAGNOSTIC_TEST Urine and Blood Test

Study Locations (1)

Ohio

  • Cleveland Clinic Main Campus - Cleveland

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-02-27
Est. Completion 2026-02-01
The Cleveland Clinic

688 total trials

What the registry record for NCT05761743 still lists

NCT05761743 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Urine and Blood Test is the first listed.

NCT05761743 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05761743 about?

NCT05761743 is a clinical study titled "Glycemic Control, Type II Diabetes, Parathyroidectomy". The purpose of this study is to assess glycemic control after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus.

What is the current status of trial NCT05761743?

This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2023-02-27. Estimated completion is 2026-02-01.

What conditions does trial NCT05761743 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Primary Hyperparathyroidism.

What interventions are being tested in trial NCT05761743?

The interventions under investigation include: Urine and Blood Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05761743?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05761743 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05761743's enrollment target sits among peer trials

80 175th of 327 higher than 150 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05761743, the US trial registry maintained by the National Library of Medicine. NCT05761743 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.